309 related articles for article (PubMed ID: 18305577)
1. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
[TBL] [Abstract][Full Text] [Related]
2. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
[TBL] [Abstract][Full Text] [Related]
3. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
[TBL] [Abstract][Full Text] [Related]
4. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
5. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
[TBL] [Abstract][Full Text] [Related]
6. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
9. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
10. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
[TBL] [Abstract][Full Text] [Related]
11. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
Blanchard M; Shim KG; Grams MP; Rajani K; Diaz RM; Furutani KM; Thompson J; Olivier KR; Park SS; Markovic SN; Pandha H; Melcher A; Harrington K; Zaidi S; Vile R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):577-87. PubMed ID: 26461000
[TBL] [Abstract][Full Text] [Related]
12. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
Leveille S; Goulet ML; Lichty BD; Hiscott J
J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
14. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
15. Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses.
Huff AL; Evgin L; Thompson J; Kottke T; Driscoll CB; Tonne J; Wongthida P; Schuelke M; Shim KG; Mer G; Ramirez-Alvarado M; Vile R
Mol Ther; 2020 Dec; 28(12):2540-2552. PubMed ID: 32877695
[TBL] [Abstract][Full Text] [Related]
16. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
17. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.
Rommelfanger DM; Wongthida P; Diaz RM; Kaluza KM; Thompson JM; Kottke TJ; Vile RG
Cancer Res; 2012 Sep; 72(18):4753-64. PubMed ID: 22836753
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
19. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
[TBL] [Abstract][Full Text] [Related]
20. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]